Donepezil Tied to Risk for Overactive Bladder
Risk for overactive bladder varies across individual cholinesterase inhibitor drugs
Alzheimer Disease and Dementia
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Investigational Alzheimer Disease Treatment Granted Fast Track Status
The FDA granted lecanemab Breakthrough Therapy designation back in June, 2021.
Biogen Cuts Price of Controversial Aduhelm in Half
Drug shows promise in clearing brain plaques believed to play a role in Alzheimer disease
ARIA Described From Clinical Trials of Aducanumab for Alzheimer Disease
Amyloid-related imaging abnormalities-edema seen on brain MRI most common adverse event in participants receiving high-dose aducanumab
Mirtazapine Does Not Reduce Agitation in Dementia Patients
In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo
FDA Clears Language Independent Computerized Test to Detect Cognitive Impairment
By using animal images, the test avoids cultural or educational bias and can be used repeatedly with no learning effect.
FDA Assigns PDUFA Date for Donepezil Transdermal System
Adlarity is a once-weekly transdermal formulation of donepezil.
Levetiracetam Well Tolerated for Alzheimer Disease
Does not improve primary outcome, but did improve performance on certain cognitive tasks in those with epileptiform activity
Most With AD, MCI Would Have Been Excluded From Aducanumab Clinical Trials
Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria
